Abstract
A series of novel 4-anilinoquinazoline derivatives (3a-3j) has been synthesized and evaluated as potential inhibitors for protein kinases implicated in Alzheimer's disease. Among all the synthesized compounds, compound 3e (N-(3,4-dimethoxyphenyl)-6,7-dimethoxyquinazolin-4-amine) exhibited the most potent inhibitory activity against CLK1 and GSK-3α/β kinase with IC₅₀ values of 1.5 μM and 3 μM, respectively. Docking studies were performed to elucidate the binding mode of the compounds to the active site of CLK1 and GSK-3β. The results of our study suggest that compound 3e may serve as a valuable template for the design and development of dual inhibitors of CLK1 and GSK-3α/β enzymes with potential therapeutic application in Alzheimer's disease.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Bioorganic & Medicinal Chemistry |
| Vol/bind | 22 |
| Udgave nummer | 6 |
| Sider (fra-til) | 1909–1915 |
| ISSN | 0968-0896 |
| DOI | |
| Status | Udgivet - 2014 |
Finansiering
The authors gratefully acknowledge the Sophisticated Analytical Instrumentation Facility (SAIF); Panjab University, Chandigarh for the NMR spectral analysis of the compounds used in this study. DG wishes to thank AICTE, New Delhi for a postgraduate fellowship. The work was also supported by the EEC FP7-KBBE-2012 BlueGenics grant (LM), ‘Institut National contre le Cancer’ (INCa) GLIOMER program and the ‘Fonds Unique Interministériel’ (FUI) PHARMASEA project (LM).
Fingeraftryk
Dyk ned i forskningsemnerne om 'Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver